Evidence map›Paper›PMID 31183660›Full record

ArticleInternational urology and nephrology2019

Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience.

Riyad Peeraully, Christine Lam, Nikita Mediratta, Ramnik Patel, Alun Williams, Manoj Shenoy, Nia Fraser

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Riyad PeeraullyDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK. riyad77@gmail.com.
Christine LamDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
Nikita MedirattaDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
Ramnik PatelDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.ORCID http://orcid.org/0000-0003-1874-1715
Alun WilliamsDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
Manoj ShenoyDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
Nia FraserDepartment of Pediatric Urology, Nottingham Children's Hospital, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK. nia.fraser@nuh.nhs.uk.
Queen's Medical Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated the efficacy and safety outcomes of endoscopic intradetrusor botulinum toxin A (BTA) injections for the treatment of children with neuropathic bladder (NB) and non-neuropathic bladder (NNB) with or without detrusor overactivity in a single centre with a retrospective analysis.

methodsFor the period 2006-2015, children who received BTA in our hospital were analysed. They were divided into group 1, those with underlying NB and group 2, those without a clear neuropathic cause of symptoms (NNB). Data are given as percentages or medians (interquartile range).

resultsOver the study period, 52 children (28 boys, 54%) received BTA, 28 in group 1 (54%; 17 (61%) boys) and 24 in group 2 (46%; 11 (46%) boys). Age at first injection was 11.8 (9.5-14.4) years. After initial injection, 40 (77%) reported symptomatic improvement, 17 (43%) becoming dry. There was no significant difference in response to initial injection between groups (p = 0.11). Duration of improvement after first injection was 7 (5.8-14) months. Twenty-five (48%) had further injections, of whom 3 (12%) were initial non-responders. Ongoing improvement was reported in 20 (80%), 11 (44%) of whom were dry. There was no significant difference in overall response to injections between groups (p = 0.11). Of the 11 non-responders, none (0/3) improved after subsequent injection and 3 (27%) subsequently underwent major urological surgery. Of the 40 who responded, 2 (5%) underwent major surgery.

conclusionBTA injection produced symptomatic improvement in 77% of our study population, with no significant differences in response between NB and NNB groups. In 95% of those who improved, major urinary tract procedures were avoided during the period studied. None of the initial non-responders improved after subsequent BTA injection. BTA injection is effective and reliable in the management of children with NB and NNB refractory to medical therapy.

Indexed as

Administration, IntravesicalAdolescentBotulinum Toxins, Type AChildFemaleHumansInjections, IntramuscularMaleNeuromuscular AgentsRetrospective StudiesTime FactorsUrinary Bladder, NeurogenicUrinary Bladder, OveractiveBotulinum Toxins, Type ANeuromuscular AgentsBotulinum toxin AChildrenNeurogenic bladderOveractive bladderUrology

Identifiers

PMID31183660
OpenAlexW2953165636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.